论文部分内容阅读
浸润未达肌层的Ta～T_1表浅性膀胱癌占全部膀胱癌的50～70%,主要用经尿道电切除术(TUR)进行治疗,5年生存率达80%以上,这已成为一种比较定型的治疗方法。但术后1～2年内的复发率高达40～50%,成为治疗膀胱癌的重要问题之一。对复发癌可试行TUR、抗癌药物膀胱内注射疗法、温热疗法及卡介苗膀胱内注射疗法,但需做膀胱切除术的病例也不少。表浅性膀胱癌约50%为多发性,用区域选择性粘膜活检(SSMB)发现在正常粘膜中广泛存在原位癌(CIS)及不典型增生。对此可进行内镜激光疗法,利
Ta-T_1 superficial bladder cancer infiltrating into the muscle layer accounts for 50-70% of all bladder cancers, and is mainly treated by transurethral electroresurgery (TUR). The 5-year survival rate is over 80%. This has become a Comparison of stereotypes of treatment. However, the recurrence rate within 1 to 2 years after operation is as high as 40 to 50%, which is one of the important problems in the treatment of bladder cancer. For recurrent cancers, trials of TUR, anticancer drugs for intravesical injection, thermotherapy, and BCG for intravesical injections may be tried, but there are also many cases requiring cystectomy. About 50% of superficial bladder cancers are multiple, and in situ mucosal carcinoma (CIS) and dysplasia are widely found in normal mucosa by regional selective mucosal biopsy (SSMB). Endoscopic laser therapy can be used for this purpose.